Newsfeeds - Spark Newswire

2 minute read

FDA
News

Merck Reports KEYTRUDA Prolonged Recurrence-Free Survival Compared to Placebo As Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma

Today, 9:27 AM

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-716 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, met its primary endpoint of recurrence-free

MRK

4 minute read

Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates

By Shanthi Rexaline

Today, 9:27 AM

The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdicts.

ALBO

6 minute read

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs

By Shanthi Rexaline

Today, 9:27 AM

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.

ABUS

1 minute read

SVB Leerink Maintains Outperform on Merck & Co, Raises Price Target to $101

By Benzinga Newsdesk

Today, 9:27 AM

SVB Leerink analyst Daina Graybosch maintains Merck & Co (NYSE:MRK) with a Outperform and raises the price target from $99 to $101.

MRK

2 minute read

7 Stocks To Watch For July 29, 2021

By Lisa Levin

Today, 9:27 AM

Some of the stocks that may grab investor focus today are: Wall Street expects Mastercard Inc (NYSE: MA) to report quarterly earnings at $1.72 per share on revenue of $4.34 billion before the opening bell. Mastercard shares fell 0.2% to $382.88 in after-hours trading.

AZN

22 minute read

Earnings Scheduled For July 29, 2021

By Benzinga Insights

Today, 9:27 AM

Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter.

5 minute read

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More

By Shanthi Rexaline

Today, 9:27 AM

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.

ABBV

1 minute read

Merck – Bayer’s Heart Failure Treatment, Verquvo Scores European Nod

By Vandana Singh

Today, 9:27 AM

The European Commission (EC) has approved Merck & Co Inc’s (NYSE:MRK) soluble guanylate cyclase (sGC) stimulator Verquvo (vericiguat). Verquvo (2.5 mg,…

BAYRY

2 minute read

Global
News

Merck Announces VERQUVO Has Been Approved In The European Union

By Benzinga Newsdesk

Today, 9:27 AM

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has granted marketing authorization in the European Union (EU) for soluble guanylate cyclase (sGC)

MRK

2 minute read

Analyzing Merck & Co’s Unusual Options Activity

By Benzinga Insights

Today, 9:27 AM

On Tuesday, shares of Merck & Co (NYSE:MRK) saw unusual options activity. After the option alert, the stock price moved down to $76.53.

MRK